An investigation on behalf of investors of Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares over potential securities laws violations by Akcea Therapeutics, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Akcea Therapeutics, Inc. (NASDAQ: AKCA) concerning whether a series of statements by Akcea Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally.

Shares of Akcea Therapeutics, Inc. (NASDAQ: AKCA) reached $33.98 per share in March 2018.

On May 8, 2018, the U.S. Food and Drug Administration ('FDA') published briefing documents in advance of a May 10, 2018 advisory panel meeting regarding Akcea's volanesorsen product. In the briefing documents, the FDA noted that significant portions of patients treated with volanesorsen had experienced steep reductions in their blood platelet counts.

Shares of Akcea Therapeutics, Inc. (NASDAQ: AKCA) declined to $17.74 per share on May 8, 2018.